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Background: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV)
antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term
prognosis of HCV-positive residents of an isolated Japanese island and prospectively investigate the effects of IFN
treatment in comparison with the HCV-negative general population.
Methods: HCV antibody was positive in 1,343 (7.6%) of the 17,712 individuals screened. 792 HCV RNA-positive,
HBsAg-negative subjects were enrolled. 1,584 HCV antibody-negative, HBsAg-negative general residents were
sex- and age-matched to the 792 subjects. A total of 154 <70-year-old patients without liver cirrhosis (LC) or
hepatocellular carcinoma (HCC) underwent IFN treatment. The survival rate with all-cause death as the endpoint
was determined and causes of death were compared.
Results: The 10- and 20-year survival rates of the hepatitis C and general resident groups were 65.4% and 87.8%,
and 40.8% and 62.5%, respectively (p < 0.001; hazard risk ratio, 0.444; 95% confidence interval (CI): 0.389–0.507).
There were 167 liver disease-related deaths and 223 deaths from other causes in the hepatitis C group, and 7 and
451, respectively, in the general resident group. Liver disease-related death accounted for 43.8% and 1.5% of deaths
in the hepatitis C and general resident groups (p < 0.0001). The cumulative survival rate of the hepatitis C patients
without IFN (n = 328) was significantly lower than the gender- and age-matched general resident group (n = 656)
(p < 0.0001) but there was no significant difference between the IFN-treated (n = 154) and general resident groups
(n = 308).
Conclusions: In the hepatitis C group, the proportion of liver disease-related death was markedly higher, and the
survival rate lower, than the general resident group. Introduction of IFN treatment in <70-year-old patients with
hepatitis C without LC or HCC improved the survival rate to a level comparable to that of the general residents.
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Chronic hepatitis C virus (HCV) infection rarely resolves
spontaneously [1] and often causes chronic hepatitis [2],
which is likely to lead to liver cirrhosis (LC) and hepato-
cellular carcinoma (HCC) [3-6]. HCC is a major cause of
death associated with hepatitis C in Japan [7,8]. Treat-
ment with interferon (IFN), introduced clinically in the
early 1990s, normalizes transaminase levels [9,10], eradi-
cates HCV [11,12] and improves liver fibrosis [13-15].* Correspondence: rsr03768@nifty.com
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reproduction in any medium, provided the orEradication of the virus has been reported to reduce
HCC occurrence [6,16]. Overall, IFN treatment clearly
reduces the rate of liver disease-related death and
improves life expectancy [17-19]. However, no study has
investigated prospectively the long-term prognosis and
final outcomes of hepatitis C by comparing life progno-
sis with death from all causes as the endpoint using the
HCV antibody-negative general population as a control
group.
In this study, we examined the life prognosis and the
extent of improvement of life expectancy in hepatitis C
patients with IFN treatment, using the general residents
of an isolated island in Nagasaki Prefecture, Japan, as aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this island, immigration and emigration were relatively
rare; therefore, it was easier to evaluate final outcomes
and survival status. From this perspective, the number of
individuals with unspecified final outcomes was expected
to be minimized, and thus, the long-term clinical
courses of hepatitis C patients would be elucidated. Fur-
thermore, how IFN treatment improved the life progno-
sis of hepatitis C patients toward that of the general
population of the island was investigated.
Patients and methods
Patients
The subjects of this study were residents of Kamigoto is-
land at the north part of the Goto archipelago, Nagasaki
prefecture, which is located in western Japan (total
population, 23,665 in 2007) (Figure 1). The Goto archi-
pelago consists of about 140 islands, with the following
five large islands (“Goto” literally means five islands)
from the north to the south: Nakadori-jima, Waka-
matsu-jima, Naru-shima, Hisaka-jima and Fukue-jima.
These islands are located at the eastern part of the East
China Sea. The southwestern archipelago with Fukue-
jima as the center is called Shimogoto (southern part of
the five islands), while the northeastern archipelago with
Nakadori-jima as the center is termed Kamigoto (north-
ern part of the five islands).
We initiated hospital-funded, free screening for HCV
antibody prevalence (by ELISA) of subjects who visited
the medical institute or underwent medical check-ups inTokyo
The Goto islands (litera
archipelago") in Nagas







Figure 1 Research area. The subjects resided in a district located in the n
western Japan.January 1990. As of March 2007, 17,712 individuals had
been tested. Of these, 1,343 (7.6%) were positive for
HCV antibody and 1,023 (76.2%) underwent the second-
ary work-up test. After the exclusion of HBsAg-positive
individuals, 792 patients positive for HCV RNA were en-
rolled in this study as the hepatitis C group (Figure 2).
All people invited to take part in this prospective cohort
study agreed to participate.
Meanwhile, from the 15,534 subjects remaining after
the exclusion of HBsAg-positive individuals from the
16,369 negative for HCV antibody in the screening test,
two local residents per hepatitis C group member were
chosen for the general resident group (1,584 subjects) as
sex- and age-matched controls. It should be noted that
local residents who had their birthdays close to those of
the patients in the hepatitis C group were chosen se-
quentially from the general resident group so that ages
at the time of the follow-up would closely match be-
tween the two groups.
Interferon therapy
IFN treatment was introduced in April 1992, when it
was approved by the national insurance in Japan. We
encouraged patients who were <70 years of age and had
persistent abnormal transaminase levels (>40 IU/mL),
but without LC or HCC, to receive IFN treatment.
Treatment was performed only when informed consent
was obtained.
Liver biopsy was carried out within four weeks of the








orthern region of the Goto islands in Nagasaki prefecture in
17,712 residents tested for screening 
1,343 anti-HCV positive 16,369 anti-HCV negative
810 positive for HCV RNA
792 CH-C subjects
835 excluded (HBsAg positive)
310 excluded 
182 CH-C ≥ 70-year-old (treated with IFN = 4, SVR = 1, non-SVR = 3)
128 CH-C < 70-year-old ,complicated with HCC and / or LC (treated with IFN = 7, SVR = 2, non-SVR = 5)
Group A1: 72 CH-C with SVR Group A1′: 144 control residents
Group A2: 82 CH-C with non-SVR Group A2′: 164 control residents
Group B: 328 CH-C untreated with IFN Group B′: 656 control residents
533 excluded (213 HCV RNA negative, 320 not tested)
15,534 negative for HBsAg
Group A: 154 CH-C treated with IFN Group A′:308 control residents
CH-C, chronic hepatitis C ; LC, liver cirrhosis;  SVR, sustained virological response 
482 CH-C <70-year-old, 
uncomplicated with HCC and  / or LC 
18 excluded (HBsAg positive)
1,584 matched control residents
Figure 2 Schema for the subjects.
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of Desmet et al., [20] where the staging of fibrosis was
defined as F0 (no fibrosis), F1 (mild fibrosis), F2 (moder-
ate fibrosis), F3 (sever fibrosis), or F4 (cirrhosis). Natural
IFN-α, recombinant IFN-α 2a, IFN-α2b or IFN-β was
selected for IFN monotherapy and given for 8 to 24
weeks. Since 2002, a combination of IFN and ribavirin
has been given for 24 to 48 weeks.
IFN was used in 165 cases up to November 2010: 161
were younger than 70 years, and 4 were 70 years or
older. Of these 165 cases, 135 and 30 underwent IFN
treatment for the first time and as retreatment, respect-
ively. HCV RNA was persistently negative for six
months or longer after the end of the treatment (i.e.,
sustained virological response, SVR) in 75 cases (45.5%).
Of the 792 patients in the hepatitis C group, 182 were
70 years or older, and 610 were younger than 70 years.
As shown in Figure 2, the 482 cases younger than 70
years without LC or HCC were categorized into sub-
groups and the efficacy of IFN treatment was evaluated
separately. The subgroup composition was as follows:
Group A, 154 patients who underwent IFN treatment;
Group A1, 72 with SVR; Group A2, 82 with non-SVR;
and Group B, 328 without IFN treatment.
Two local residents who were sex- and age-matched
to each member of subgroups A, A1, A2, and B in the
hepatitis C group were chosen. The subgroups of the
general residents were designated as A0 (n = 308), A10
(n = 144), A20 (n = 164), and B0 (n = 656), respectively.Follow-up and diagnosis of HCC
The day of the screening test for HCV antibody was
designated the starting day for follow-up. Subjects were
followed-up until August 2011. In addition, in the ana-
lysis of the efficacy of IFN therapy, the day of introduc-
tion of IFN therapy was the starting day of follow-up of
groups A, A1, A2, and B. LC was diagnosed by liver bi-
opsy and laparoscopy. LC was diagnosed when typical
images for LC were observed by abdominal ultrasonog-
raphy and/or CT, and esophageal or gastric varices were
concomitantly observed endoscopically.
Imaging diagnosis of HCC was made at least twice per
year. Space-occupying lesions detected or suspected at
the time of ultrasonography were further examined with
computed tomography, Magnet resonance imaging sys-
tem, selective hepatic angiography, and fine-needle as-
piration biopsy. Clinical trends of tumor markers were
also taken into account. A final diagnosis of HCC was
based on histological findings from resected hepatic
tumors or biopsy specimens, or on the radiological find-
ings of selective hepatic angiography.Ethics considerations
The test results were explained to the subjects after
informed consent was obtained. The study protocol was
approved by the Ethics Committee of Kamigoto Hospital
(reference number: 06–03) in accordance with the Dec-
laration of Helsinki.
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Statistical analysis was performed using SPSS version
19.0J for Windows. The level of statistical significance
was set at p < 0.05. Continuous variables are expressed
as mean ± standard deviation. Differences of means were
evaluated using Student’s t–test or the Mann–Whitney
U–test. Discrete variables were analyzed using the chi-
squared test. Cumulative survival curves were deter-
mined using the Kaplan–Meier method. The values of
the confidence intervals (CIs) indicate the lower and
upper 95% confidence limits.Results
Baseline patient characteristics
Table 1 shows the backgrounds of the 792 cases in the
hepatitis C group and 1,584 cases of the general resi-
dent group. At the first visit, LC was observed in 177
(22.3%) and 8 cases (0.4%) in the hepatitis C and general
resident groups, respectively; HCC was present at the
first visit in 45 (5.7%) and 2 cases (0.1%), respectively.
Both diseases were diagnosed significantly more often in
the hepatitis C group (p < 0.001). IFN treatment was
introduced during the follow-up in 165 cases (20.8%) in
the hepatitis C group and in no cases in the general
resident group.
During the follow-up, laparoscopy, liver biopsy, or both
were carried out in 446 cases (56.3%) in the hepatitis C
group. HCV serogroups or genotypes were determined in
742 of the 792 cases (93.7%) in the hepatitis C group.
Serotype 1 or genotype 1b was observed in 437 cases






Male: Female 512: 280 1024: 560 matched
Birth year −1929 320 640 matched
−1939 279 558 matched
1940- 193 386 matched
Age at first visit
(mean ± SD), years
60.9 ± 12.3 60.9 ± 12.3 matched
LC at first visit 177 (22.3%) 8 (0.4%) < 0.001
HCC at first visit 45 (5.7%) 2 (0.1%) < 0.001
Liver biopsy/laparoscopy
(F0–1 : F2 : F3 : F4)
446 (56.3%)
(182 : 83 : 42 : 139)
IFN administration 165 (20.8%) 0 (0%)
SVR 75 (45.5%)
Non-SVR 90 (54.5%)
Outcomes Survival 327 (41.3%) 1031 (65.1%) < 0.0001
Death 400 (50.5%) 482 (30.4%)
Unknown 65 (8.2%) 71 (4.5%)in 270 cases (36.4%), and serotypes or genotypes were
unidentified in 35 cases (4.7%).
Survival, death, and unknown status at the final
follow-up were observed in 327 (41.3%), 400 (50.5%),
and 65 cases (8.2%) in the hepatitis C group and 1,031
(65.1%), 482 (30.4%), and 71 cases (4.5%) in the general
resident group, respectively. The median follow-up peri-
ods were 11.5 years (maximum, 21.7 years) and 16.1
years (maximum, 21.7 years) for the hepatitis C and general
resident groups, respectively.
Survival rate
With death from all causes as the endpoint, the survival
rates in the hepatitis C and general resident group were
83.7% and 94.5% at 5 years, 65.4% and 87.8% at 10 years,
52.9% and 76.8% at 15 years, and 40.8% and 62.5% at
20 years, respectively. The survival rate was significantly
lower in the hepatitis C group (p < 0.001, Figure 3). The
hazard risk ratio was 0.444 (95% CI: 0.389–0.507).
Causes of death
The causes of death of the 400 and 482 patients in the
hepatitis C and general resident groups who died during
the follow-up period were analyzed. In particular, the
proportions of liver disease-related deaths such as death
from HCC, liver failure, or gastrointestinal bleeding and
other causes of death were compared between groups.
As shown in Figure 4, out of 390 cases excluding 10
(2.5%) with an unidentified cause of death out of 400
fatal cases in the hepatitis C group, there were 167 liver
disease-related deaths (42.8%; 145 HCC, 19 liver failure,
and 3 gastrointestinal bleeding) and 223 deaths from
other causes (57.1%; 100 other malignant tumor, 36
pneumonia, 19 heart disease, 15 cerebral vascular dis-
ease, 53 others). On the other hand, out of 458 cases, ex-
cluding 24 (5.0%) with an unidentified cause of death
from the 482 fatal cases in the general resident group,
there were 7 liver disease-related deaths (1.5%; 5 HCC, 2
liver failure and 0 gastrointestinal bleeding) and 451
deaths from other causes (98.5%).
The average ages at the time of death were 73.2 ± 8.3
years (n = 279) in males and 78.2 ± 9.8 years (n = 121)
in females in the hepatitis C group; those in the general
resident group were 79.1 ± 8.6 years (n = 338) and 83.4
± 8.8 years (n = 144), respectively. The average ages at
the time of death were significantly lower for both sexes
in the hepatitis group (p < 0.001).
Interventional effect of IFN therapy
The A, A1, A2, and B subgroups, younger than 70 years
and without LC or HCC, consisted of 482 cases in the
hepatitis C group (n = 792), in which IFN treatment was
































Time (yr) 5 10 15 20
Figure 3 Cumulative survival rates in the hepatitis C and
control groups. All-cause mortality was adopted as the endpoint
and the results were analyzed using the Kaplan-Meier method. The
hazard ratio was 0.444 (95% CI: 0.389–0.507). The solid and dotted
lines indicate the hepatitis C and control groups, respectively.














Male 117 (76.0%) 56 (77.8%) 62 (75.6%) 205 (62.5%)
Age at first visit
(mean ± SD), years
56.9 ± 11.5 55.7 ± 12.6 58.0 ± 10.3 57.5 ± 10.4
ALT < 40 IU/mL 2 (1.3%) 0 (0%) 2 (2.4%) 129 (39.4%)
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subgroups (A0, A10, A20, and B0).
The background data of Groups A, A1, A2, and B are
shown in Table 2. The proportions of males were signifi-
cantly higher in Groups A, A1, and A2, in which IFN
was introduced, than that in Group B, in which IFN was
not introduced (p = 0.003, p = 0.013, and p = 0.045, re-
spectively). There were no significant differences in age
between the groups. ALT levels 40 IU/mL (the upper0%
50%
100%



















Figure 4 Causes of death in the hepatitis C and general
resident groups after excluding cases with indeterminate
causes of death. Liver disease-related deaths, such as deaths due
to HCC, hepatic failure and gastrointestinal bleeding accounted for
42.8% (n = 167) of cases in the hepatitis C group and 1.5% (n = 7)
of cases in the general resident group.limit of normal) or lower were observed 95% of the time
or more during the follow-up period in 2 (1.3%), 0 (0%),
2 (2.4%), and 129 (39.4%) cases in Groups A, A1, A2,
and B, respectively. Such results were observed signifi-
cantly more often in Group B than in all other groups
(p < 0.001 in all comparisons).
The cumulative survival rates in Groups A, A1, A2, and
B in the hepatitis C group were compared to their corre-
sponding groups in the general resident group (Figure 4).
In Groups A and A0, the 5-, 10-, and 15-year survival rates
were 94.5% and 96.9%, 86.5% and 89.8%, and 76.9% and
82.0%, respectively. Irrespective of the effect of treatment,
there was no significant difference in the survival rates be-
tween cases receiving IFN therapy and the general resi-
dent group (Figure 5A).
In Groups A1 and A10, the 5-, 10-, and 15-year survival
rates were 94.0% and 96.3%, 87.1% and 87.4%, and 80.1%
and 79.2%, respectively. The survival rates were not signifi-
cantly different between groups (Figure 5C). In Groups A2
and A20, the 5-, 10-, and 15-year survival rates were 95.1%
and 97.5%, 86.1% and 91.6%, and 74.6% and 83.8%, re-
spectively. The survival rates were lower in Group A2, but
the difference was not significant (p = 0.153, Figure 5D).
In Groups B and B0, the 5-, 10-, and 15-year survival
rates were 92.4% and 97.4%, 77.7% and 93.0%, and 64.2%
and 84.6%, respectively. The survival rates were signifi-
cantly lower in Group B (p < 0.001, Figure 5B).
The causes of death were compared specifically in
cases with ALT levels of 40 IU/mL or more during the
follow-up period in Groups A, A1, A2, and B, and the
influence of IFN therapy on the cause of death was
examined (Table 3). During the follow-up period, there
were 25, 9, 16, and 90 deaths in Groups A, A1, A2, and
B, respectively. Among the deaths, liver disease-related
deaths were observed in 6 (24%), 1 (11.1%), 5 (31.2%),
and 32 cases (36.0%) in Groups A, A1, A2, and B, re-
spectively, excluding cases with unknown causes of
death (0, 0, 0, and 1 cases, respectively). Despite the lack
of significant differences, the proportion of liver disease-
related death was lower in Group A1 than in Group B.Discussion
In this study, we compared prospectively the life expect-
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Figure 5 Cumulative survival rates between corresponding groups. (A) There was no significant difference between the IFN-treated hepatitis
C group (Group A) and the general resident group (Group A0). (B) There was a significant difference between the hepatitis C group not receiving
IFN treatment (Group B) and the general resident group (Group B0) (p < 0.0001). (C) There was no significant difference between the hepatitis C
group that achieved SVR by IFN treatment (Group A1) and the general resident group (Group A10). (D) There was no significant difference
between the IFN treatment group with non-SVR in the hepatitis C group (Group A2) and the general resident group (Group A20) (p = 0.153). All
survival rates were calculated using the Kaplan–Meier method. Solid and dotted lines represent the hepatitis C and general resident groups,
respectively.
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antibody-negative general residents in a specific area.
The median follow-up period exceeded 10 years, the
follow-up survey was excellent in that only 10% of cases
had unknown final outcomes.
As mentioned above, because the subjects were resi-
dents of an isolated island, where immigration and emi-
gration were relatively rare, the follow-up was quite
successful. Moreover, environmental factors, such as
medical care, were comparable between the two groups
as a result of approximating birth date in the same resi-














Total deaths 25 9 16 90
Unknown cause 0 0 0 1
Liver-related 6 (24.0%) 1 (11.1%) 5 (31.2%) 32 (36.0%)
Others 19 (76.0%) 8 (88.9%) 11 (68.8%) 57 (64.0%)matched the subjects in the hepatitis C group. Further-
more, the accuracy of the comparative study in cases
with and without persistent HCV infection was consid-
ered to be excellent.
Hepatocarcinogenesis can be prevented in hepatitis C
when HCV is persistently undetectable and transami-
nases are normalized by IFN treatment [6,21-23]. In
addition, it is reported that IFN treatment improves the
life prognosis in hepatitis C [17,18,24-27]. However, no
report has prospectively examined the effect of IFN
treatment with HCV antibody-negative general residents
as controls; to our knowledge, the present study is the
first of its kind.
In terms of the overall prognosis of hepatitis C, the
survival rate was lower than in the HCV antibody-
negative general residents; the hazard ratio was 0.444
(95% CI: 0.389–0.507). Liver disease-related death
accounted for 42.8% of all causes of death in the hepa-
titis C group; this greatly exceeded the 1.5% for the
general residents. The survival rate in the patients per-
sistently infected with HCV was markedly low and their
prognosis was extremely poor.
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improved the prognosis of the hepatitis C group. The
patients younger than 70 years who had indications for
IFN treatment and had no LC or HCC were compared
to the general resident group. When SVR was obtained
by IFN treatment, the prognosis in the hepatitis C group
was comparable to that in the general resident group.
Kaplan–Meier analysis showed almost overlapping
curves for the two groups. In cases with non-SVR, des-
pite the slightly lower survival rates in the general resi-
dent group, the prognosis in the hepatitis C group was
not significantly different. Taken together, irrespective of
the effect of IFN treatment, the survival rate of members
of the hepatitis C group who received IFN treatment
was comparable to that of the general resident group.
Yoshida et al. [18] reported that the standardized mor-
tality rate from all causes was 1.4 (0.8–2.3) in a non- LC
group without IFN treatment compared to 0.3 (0.1–0.7)
in an SVR group after IFN treatment and 0.7 (0.5–1.1)
in a non-SVR group after IFN treatment; these results
are consistent with ours. It may be reasonable to con-
clude that to a certain extent, intervention with IFN
treatment eliminates the risk of hepatocarcinogenesis
due to persistent long-term infection with HCV. Fur-
thermore, achieving SVR eliminates the risk almost com-
pletely. Even in cases with non-SVR, the risk of
hepatocarcinogenesis was reduced and the prognosis be-
came closer to that of the general resident group.
Regarding the results obtained using death from all
causes as the endpoint, we presumed the following: First,
the group receiving IFN treatment had a higher aware-
ness of health management and continued periodical
medical check-ups and clinic visits with a greater fre-
quency than the group without IFN treatment. Second,
we presumed that this higher awareness of health man-
agement had a preventive effect against a variety of dis-
eases in addition to liver disease and enabled effective
treatment following early disease detection.
In this study, IFN treatment introduction was not
assigned randomly; therefore, there was a difference in
the backgrounds between the two groups. There was a
bias in that the IFN–treated group had a higher propor-
tion of males and more cases with ALT values exceeding
the normal range. In general, male sex and high trans-
aminase levels are risk factors for hepatocarcinogenesis;
the survival rate in such cases is low [2,7,8]. However,
even in such cases with a high risk for hepatocarcino-
genesis, introduction of IFN treatment reduced the mor-
tality from HCC and improved the survival rate;
furthermore, the prognosis was comparable to that in
the general resident group.
Yoshida et al. reported that IFN treatment improved
the prognosis of hepatitis C in a retrospective cohort
study [18]. Although their conclusion is consistent withours, our study is a prospective cohort study, and the
median of the follow-up period exceeded 10 years.
Moreover, our study is unique in that it is a comparative
study with HCV antibody-negative general residents of
the same district in the same time period as controls.
Nagao et al. carried out a survey of patients infected
with HCV in a district of Japan and reported that the
factors that influence the acceptance of IFN treatment
are the clinics the patients visited, sex, and the presence
or absence of concomitant disease [28]. Because patients
infected with HCV have been getting older in Japan, co-
operation between liver specialists and non-experts in
individual districts is important to introduce IFN treat-
ment as early as possible, particularly for people under
70 years.
Conclusion
We compared the final outcomes and prognosis between
all patients with hepatitis C and HCV antibody-negative
general residents in the district. In conclusion, persistent
infection with HCV led to a markedly poor prognosis,
but introduction of IFN treatment before the age of 70
years reduced the risk associated with HCV infection
and improved the prognosis to a level comparable to
that of the general population.
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